CLINICAL STUDY
Prognostic implications of Tc-99m sestamibi viability imaging and subsequent therapeutic strategy in patients with chronic coronary artery disease and left ventricular dysfunction
Roberto Sciagrà, MDa,
Marco Pellegri, MDa,
Alberto Pupi, MDa,
Leonardo Bolognese, MD*,
Gianni Bisi, MD ,
Vito Carnovale, MDa* and
Giovanni M. Santoro, MD*
a Nuclear Medicine Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy
* Division of Cardiology, Careggi Hospital, Florence, Italy
Nuclear Medicine, University of Turin, Turin, Italy
Manuscript received October 21, 1999;
revised manuscript received March 15, 2000,
accepted April 26, 2000.
Reprint requests and correspondence: Dr. Roberto Sciagrà, Nuclear Medicine Unit, Department of Clinical Physiopathology, University of Florence, Viale Morgagni 85, 50134 Florence, Italy
r.sciagra{at}dfc.unifi.it
OBJECTIVES
The aim of the study was to verify the prognostic implications of viability detection using baseline-nitrate sestamibi imaging in patients with left ventricular (LV) dysfunction due to chronic coronary artery disease (CAD) submitted to different therapeutic strategies.
BACKGROUND
The prognostic meaning of preserved viability in these patients is still debated. Sestamibi is increasingly used for myocardial perfusion scintigraphy and is being accepted also as viability tracer, but no data are available about the relationship between viability in sestamibi imaging, subsequent treatment, and patient’s outcome.
METHODS
Follow-up data were collected in 105 CAD patients with LV dysfunction who had undergone baseline-nitrate sestamibi perfusion imaging for viability assessment and had been later treated medically (group 1), or submitted to revascularization, which was either complete (group 2A) or incomplete (group 2B).
RESULTS
Eighteen hard events (cardiac death or nonfatal myocardial infarction) were registered during the follow-up. A significantly worse event-free survival curve was observed in the patients of group 1 (p < 0.0002) and group 2B (p < 0.03) compared to those of group 2A. Using a Cox proportional hazard model, the most powerful prognostic predictors of events were the number of nonrevascularized asynergic segments with viability in sestamibi imaging (p < 0.003, risk ratio [RR] = 1.4), and the severity of CAD (p < 0.02, RR = 1.28).
CONCLUSIONS
Viability detection in sestamibi imaging has important prognostic implications in CAD patients with LV dysfunction. Patients with preserved viability kept on medical therapy or submitted to incomplete revascularization represent high-risk groups.
|
Abbreviations and Acronyms
| | ANOVA | = analysis of variance | | CABG | = coronary artery bypass grafting | | CAD | = coronary artery disease | | CCS | = Canadian Cardiovascular Society | | CI | = confidence interval | | EF | = ejection fraction | | LV | = left ventricular | | NYHA | = New York Heart Association | | PTCA | = percutaneous transluminal coronary angioplasty | | RR | = risk ratio | | SPECT | = single-photon emission computed tomography |
|
This article has been cited by other articles:
|
|
|
|
 
P. G. Camici, S. K. Prasad, and O. E. Rimoldi
Stunning, Hibernation, and Assessment of Myocardial Viability
Circulation,
January 1, 2008;
117(1):
103 - 114.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F.L. Schinkel, D. Poldermans, A. Elhendy, and J. J. Bax
Assessment of Myocardial Viability in Patients with Heart Failure
J. Nucl. Med.,
July 1, 2007;
48(7):
1135 - 1146.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. H.J.A. Slart, A. Agool, D. J. van Veldhuisen, R. A. Dierckx, and J. J. Bax
Nitrate Administration Increases Blood Flow in Dysfunctional but Viable Myocardium, Leading to Improved Assessment of Myocardial Viability: A PET Study
J. Nucl. Med.,
August 1, 2006;
47(8):
1307 - 1311.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zimarino, A. M. Calafiore, and R. De Caterina
Complete myocardial revascularization: between myth and reality
Eur. Heart J.,
September 2, 2005;
26(18):
1824 - 1830.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Giorgetti, A. Pingitore, B. Favilli, A. Kusch, M. Lombardi, and P. Marzullo
Baseline/Postnitrate Tetrofosmin SPECT for Myocardial Viability Assessment in Patients with Postischemic Severe Left Ventricular Dysfunction: New Evidence from MRI
J. Nucl. Med.,
August 1, 2005;
46(8):
1285 - 1293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J J Bax, E E van der Wall, and M Harbinson
Radionuclide techniques for the assessment of myocardial viability and hibernation
Heart,
August 1, 2004;
90(suppl_5):
v26 - v33.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.S. Billing, A. Ooi, and S. R. Large
The outcome of cardiac surgery in high-risk quaternary referral patients
Interactive CardioVascular and Thoracic Surgery,
September 1, 2003;
2(3):
369 - 372.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.G.F. Cleland, N. Freemantle, S.G. Ball, R.S. Bonser, P. Camici, S. Chattopadhyay, D. Dutka, J. Eastaugh, J. Hampton, S. Large, et al.
The heart failure revascularisation trial (HEART): rationale, design and methodology
Eur J Heart Fail,
June 1, 2003;
5(3):
295 - 303.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Tadamura, M. Mamede, S. Kubo, H. Toyoda, M. Yamamuro, H. Iida, N. Tamaki, K. Nishimura, M. Komeda, and J. Konishi
The Effect of Nitroglycerin on Myocardial Blood Flow in Various Segments Characterized by Rest-Redistribution Thallium SPECT
J. Nucl. Med.,
May 1, 2003;
44(5):
745 - 751.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Meluzin, J. Cerny, L. Spinarova, J. Toman, L. Groch, F. Stetka, M. Frelich, P. Hude, J. Krejci, L. Rambouskova, et al.
Prognosis of patients with chronic coronary artery disease and severe left ventricular dysfunction. The importance of myocardial viability
Eur J Heart Fail,
January 1, 2003;
5(1):
85 - 93.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
